GLAXF News and Press, GlaxoSmithKline Plc From 04/01/22

My portfolio, built specifically for my retirement ~20+ years from now, experiences some major shifts as I play for upside in oil and a big biotech trade. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helping ...

Analysts continue to disbelieve that the Pfizer/BioNTech Comirnaty vaccine can have a future, while reality shows boosters are needed. Pfizer’s earnings from Comirnaty continue to distort the price of Pfizer stock; this will continue. The more difficult issue is to understa...

Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth your time for further analy...

After poor performance during 2015 to 2018, IXJ reshuffled its portfolio. Price return in the past 3 years is good and even better in the longer period. Price multiples suggest that IXJ is neither undervalued nor overvalued. For further details see: IXJ: A Healthcare ETF...

DTH invests in high yield stocks of developed countries excluding North America. More than half of asset value is in Japan, the U.K. and Australia. It is heavy in financials, materials and communication. Inflation-adjusted total return after tax since inception is close to fla...

Theravance failed 3 trials last year. There was a major restructuring and change of focus. A small revenue stream from YUPELRI is its only positive, but that doesn't justify the valuation. For further details see: Theravance: All-Round Failure

GlaxoSmithKline PLC (GSK) UBS Global Consumer and Retail Conference 2022 March 9, 2022 11:00 AM ET Company Participants Tobias Hestler - Haleon, Designate Chief Financial Officer Conference Call Participants Guillaume Delmas - UBS Presentation Guillaume Delmas Hello, everyone, and welcome to ...

GlaxoSmithKline plc (GSK) 42nd Annual Cowen Health Care Conference Call March 7, 2022 11:10 ET Company Participants Hal Barron - Chief Scientific Officer and President, Research and Development Conference Call Participants Stephen Scala - Cowen & Company Presentation Stephen Scala Good mo...

Unilever is one of the best consumer staples stocks you can find. The current hostile environment presents big challenges for all staples, but Unilever's valuation discounts those risks adequately. We are upgrading this to a Buy with a 2-year price target of $50 per share. F...

The following slide deck was published by GlaxoSmithKline plc in conjunction with this event. For further details see: GlaxoSmithKline PLC (GSK) Investor Presentation - Slideshow